Advances in COVID-19 vaccine development and clinical application / 中国药理学通报
Chinese Pharmacological Bulletin
; (12): 610-616, 2023.
Article
在 Zh
| WPRIM
| ID: wpr-1013928
Responsible library:
WPRO
ABSTRACT
Severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) has spread to more than 220 countries, including China. With the deepening of research on the viral molecular structure and pathogenesis of SARS-COV-2, various prevention strategies and treatment plans for coronavirus disease 2019 (COVID-19) are being actively explored. Pharmaceutical companies and scientific research institutions in many countries or regions are also actively engaged in the research and development of COVID-19 vaccines. More than 300 COVID-19 vaccine candidates are currently under study globally, and more than 10 have entered phase III clinical trials or are authorized for emergency use. Five COVID-19 vaccines have been approved for use in China, including three inactivated vaccines, one type 5 adenovirus vector vaccine and one recombinant protein vaccine (from CHO cell). The COVID-19 vaccines developed by Oxford University/Astrazeneca and Johnson & Johnson are adenovirus vector vaccines. Emergency licensing of mRNA vaccines developed by Pfizer and BioNTech, and mRNA vaccines developed by Moderna also offer potential prospects for COVID-19 prevention and control. This article reviews the development and clinical application of COVID-19 vaccines.